Barnes, TR, Curson, DA. Long-term depot antipsychotics. A risk–benefit assessment. Drug Saf
1994; 10: 464–79.
Jann, MW, Ereshefsky, L, Saklad, SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet
1985; 10: 315–33.
Stauning, JA, Kirk, L, Joorgensen, A. Comparison of serum levels after intramuscular injections of 2% and 10% cis(Z)-flupentixol decanoate in Viscoleo to schizophrenic patients. Psychopharmacology (Berl)
1979; 65: 69–72.
Tuninger, E, Levander, S. Large variations of plasma levels during maintenance treatment with depot neuroleptics. Br J Psychiatry
1996; 169: 618–21.
Wiles, DH, Gelder, MG. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol
1979; 8: 565–70.
Curry, SH, Whelpton, R, De Schepper, PJ, Vranckx, S, Schiff, AA. Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol
1979; 7: 325–31.
Ereshefsky, L, Jann, MW, Saklad, SR, Davis, CM, Richards, AL, Burch, NR. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry
1985; 20: 329–32.
Kissling, W, Moller, HJ, Walter, K, Wittmann, B, Krueger, R, Trenk, D. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention. Pharmacopsychiatry
1985; 18: 240–5.
Jann, MW, Saklad, SR, Ereshefsky, L, Richards, AL, Harrington, CA, Davis, CM. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology
1986; 90: 468–70.
Nayak, RK, Doose, DR, Nair, NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol
1987; 27: 144–50.
Knudsen, P, Hansen, LB, Larsen, NE. Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications. Acta Psychiatr Scand Suppl
1985; 322: 11–4.
Larsen, NE, Hansen, LB. Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks. Ther Drug Monit
1989; 11: 642–6.
Kistrup, K, Gerlach, J, Aaes-Jorgensen, T, Larsen, NE. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. Psychopharmacology (Berl)
1991; 105: 42–8.
Girard, M, Granier, F, Schmitt, L, Cotonat, J, Escande, M, Blanc, M. [Initial results of a pharmacokinetic study of pipothiazine and its palmitic ester (Piportil L4) in a schizophrenic population]. Encephale
1984; 10: 171–6.
Altamura, AC, Sassella, F, Santini, A, Montresor, C, Fumagalli, S, Mundo, E. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs
2003; 63: 493–512.
Viala, A, Hou, N, Ba, B, Durand, A, Dufour, H, D'Agostino, N, et al. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. Psychopharmacology (Berl)
1984; 83: 147–50.
Poulsen, JH, Olesen, OV, Larsen, NE. Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo. Ther Drug Monit
1994; 16: 155–9.
Jorgensen, A, Overo, KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels. Acta Psychiatr Scand Suppl
1980; 279: 41–54.
Viala, A, Ba, B, Durand, A, Gouezo, F, Hou, N, Jorgensen, A. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology (Berl)
1988; 94: 293–7.
Kurtz, D, Bergstrom, R, McDonnell, D, Mitchell, M. Pharmacokinetics (PK) of multiple doses of olanzapine long-acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophrenia. Biol Psychiatry
2008; 63 (suppl 1): 228S.
Ramstack, M, Grandolfi, GP, Mannaert, E, D'Hoore, P, Lasser, RA. Long-acting risperidone: prolonged-release injectable delivery of risperidone using Medisorb microsphere technology. Schizophr Res
2003; 60 (suppl 1): 314.
Gefvert, O, Eriksson, B, Persson, P, Helldin, L, Bjorner, A, Mannaert, E, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophrenia. Int J Neuropsychopharmacol
2005; 8: 27–36.
Agrup-Andersson, L, Bengtsson, A, Erlandsson, K, Gottfries, CG, Witzell-Ostlund, G. Flupenthixol decanoate. Controlled investigation concerning dosage. Acta Psychiatr Scand Suppl
1974; 255: 7–14.
McCreadie, RG, Flanagan, WL, McKnight, J, Jorgensen, A. High dose flupenthixol decanoate in chronic schizophrenia. Br J Psychiatry
1979; 135: 175–9.
Johnson, DA, Ludlow, JM, Street, K, Taylor, RD. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br J Psychiatry
1987; 151: 634–8.
Cookson, IB. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. Int Clin Psychopharmacol
1987; 2: 141–9.
Carpenter, WT, Buchanan, RW, Kirkpatrick, B, Lann, HD, Breier, AF, Summerfelt, AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry
1999; 156: 412–8.
Geller, J. Use of extremely low doses of fluphenazine decanoate. Am J Psychiatry
1990; 147: 672.
Marder, SR, Van Putten, T, Mintz, J, Lebell, M, McKenzie, J, May, PR. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry
1987; 44: 518–21.
Capstick, N. Long-term fluphenazine decanoate maintenance dosage requirements of chronic schizophrenic patients. Acta Psychiatr Scand
1980; 61: 256–62.
Kane, JM, Davis, JM, Schooler, N, Marder, S, Casey, D, Brauzer, B, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry
2002; 159: 554–60.
Taylor, D. Establishing a dose–response relationship for haloperidol decanoate. Psychiatr Bull
2005; 29: 104–7.
Eklund, K, Forsman, A. Minimal effective dose and relapse – double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol
1991; 14 (suppl 2): S7–12.
Omerov, M, Wistedt, B, Bolvig-Hansen, L, Larsen, NE. The relationship between perphenazine plasma levels and clinical response in acute schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry
1989; 13: 159–66.
Mazure, CM, Nelson, JC, Jatlow, PI, Kincare, P, Bowers, MB. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. J Clin Psychiatry
1990; 51: 330–4.
Knudsen, P, Hansen, LB, Hojholdt, K, Larsen, NE. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatr Scand Suppl
1985; 322: 29–40.
Knudsen, P, Hansen, LB, Hojholdt, K, Larsen, NE. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatr Scand Suppl
1985; 322: 41–50.
Gallant, DM, Mielke, D, Bishop, G, Oelsner, T, Guerrero-Figueroa, R. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients. Dis Nerv Syst
1975; 36: 193–6.
Schmidt, K. Pipothiazine palmitate: a versatile, sustained-action neuroleptic in psychiatric practice. Curr Med Res Opin
1986; 10: 326–9.
Burch, EA, Ayd, FJ. Depot pipotiazine 1970–1982: a review. J Clin Psychiatry
1983; 44: 242–7.
Solgaard, T, Kistrup, K, Aaes-Jorgensen, T, Gerlach, J. Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum effective dose and corresponding serum levels. Pharmacopsychiatry
1994; 27: 119–23.
Wistedt, B, Koskinen, T, Thelander, S, Nerdrum, T, Pedersen, V, Molbjerg, C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand
1991; 84: 14–21.
Lauriello, J, Lambert, T, Andersen, S, Lin, D, Taylor, CC, McDonnell, D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry
2008; 69: 790–9.
Gharabawi, GM, Gearhart, NC, Lasser, RA, Mahmoud, RA, Zhu, Y, Mannaert, E, et al. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry
2007; 6: 3.
Moller, HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs
2007; 67: 1541–66.
Kane, JM, Eerdekens, M, Lindenmayer, JP, Keith, SJ, Lesem, M, Karcher, K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry
2003; 160: 1125–32.
Keks, NA, Ingham, M, Khan, A, Karcher, K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry
2007; 191: 131–9.
Taylor, DM, Young, C, Patel, MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol
2006; 9: 685–94.
Bai, YM, Ting, CT, Chen, JY, Chang, WH, Wu, B, Hung, CH, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry
2007; 68: 1218–25.
Kapur, S, Zipursky, R, Jones, C, Remington, G, Houle, S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry
2000; 157: 514–20.
Agid, O, Mamo, D, Ginovart, N, Vitcu, I, Wilson, AA, Zipursky, RB, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response. A double-blind PET study in schizophrenia. Neuropsychopharmacology
2006; 32: 1209–15.
Baron, JC, Martinot, JL, Cambon, H, Boulenger, JP, Poirier, MF, Caillard, V, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl)
1989; 99: 463–72.
Nyberg, S, Farde, L, Halldin, C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Arch Gen Psychiatry
1997; 54: 953–8.
Nyberg, S, Farde, L, Halldin, C, Dahl, ML, Bertilsson, L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry
1995; 152: 173–8.
Talvik, M, Nordstrom, AL, Larsen, NE, Jucaite, A, Cervenka, S, Halldin, C, et al. A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl)
2004; 175: 148–53.
Mamo, D, Kapur, S, Keshavan, M, Laruelle, M, Taylor, CC, Kothare, PA, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology
2008; 33: 298–304.
Remington, G, Mamo, D, Labelle, A, Reiss, J, Shammi, C, Mannaert, E, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry
2006; 163: 396–401.
Haddad, PM, Taylor, M, Niaz, OS. First-generation antipsychotic long-acting injections v. oral antipsychotric medication in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry
2009; 195 (suppl 52): s20–8.
Adams, CE, Fenton, MKP, Quraishi, S, David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry
2001; 179: 290–9.
Eberhard, G, Hellbom, E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Acta Psychiatr Scand
1986; 74: 255–62.
Knights, A, Okasha, MS, Salih, MA, Hirsch, SR. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. Br J Psychiatry
1979; 135: 515–23.
Johnson, DAW. The side-effects of fluphenazine decanoate. Br J Psychiatry
1973; 123: 519–22.
Chouinard, G, Annable, L, Campbell, W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol
1989; 9: 247–53.
Bechelli, LPC, Iecco, MC, Acioli, A, Pontes, MC. A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic. Curr Ther Res
1985; 37: 662–71.
Wistedt, B, Persson, T, Hellbom, E. A clinical double-blind comparison between haloperidol decanoate and fluphenazine decanoate. Curr Ther Res
1984; 35: 804–14.
Wistedt, B. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. Int Clin Psychopharmacol
1986; 1 (suppl 1): 15–23.
Lindholm, H, Gullberg, B, Ohman, A, Sedvall, G. Effects of perphenazine enanthate injections on prolactin levels in plasma from schizophrenic women and men. Psychopharmacology (Berl)
1978; 57: 1–4.
Ahlfors, UG, Dencker, SJ, Gravem, A, Remvig, J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial. Acta Psychiatr Scand Suppl
1980; 279: 77–91.
Knudsen, P, Hansen, LB, Auken, G, Waehrens, J, Hojholdt, K, Larsen, NE. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand Suppl
1985; 322: 15–28.
David, A, Quraishi, S, Rathbone, J. Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev
2005; (3): CD001717.
Starmark, JE, Forsman, A, Wahlstrom, . Abscesses following prolonged intramuscular administration of perphenazine enantate. Acta Psychiatr Scand
1980; 62: 154–7.
Hay, J. Complications at site of injection of depot neuroleptics. BMJ
1995; 311: 421.
McDonnell, D, Sorsaburu, S, Brunner, E, Detke, H, Anderson, S, Bergstrom, R, et al. Post-injection delirium/sedation syndrome observed with olanzapine long-acting injection: review of the first 25 events. Eur Neuropsychopharmacol
2008; 18 (suppl 4): S437.
Schmauss, M, Sacchetti, E, Kahn, JP, Medori, R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol
2007; 22: 85–92.
Niaz, OS, Haddad, PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand
2007; 116: 36–46.
Gharabawi, GM, Bossie, CA, Zhu, Y, Mao, L, Lasser, RA. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res
2005; 77: 129–39.
Kissling, W, Glue, P, Medori, R, Simpson, S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol
2007; 22: 505–13.
Gibson, AC. Depot injections and tardive dyskinesia. Br J Psychiatry
1978; 133: 361–5.
Ereshefsky, L, Saklad, SR, Jann, MW, Davis, CM, Richards, A, Seidel, DR. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry
1984; 45: 50–9.
Taylor, D, Mir, S, Mace, S, Whiskey, E. Co-prescribing of atypical and typical antipsychotics – prescribing sequence and documented outcome. Psychiatr Bull
2002; 26: 170–2.
Lieberman, JA, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.